» Articles » PMID: 29296851

Agonistic Targeting of TLR1/TLR2 Induces P38 MAPK-dependent Apoptosis and NFκB-dependent Differentiation of AML Cells

Abstract

Acute myeloid leukemia (AML) is associated with poor survival, and there is a strong need to identify disease vulnerabilities that might reveal new treatment opportunities. Here, we found that Toll-like receptor 1 (TLR1) and TLR2 are upregulated on primary AML CD34CD38 cells relative to corresponding normal bone marrow cells. Activating the TLR1/TLR2 complex by the agonist Pam3CSK4 in -driven human AML resulted in induction of apoptosis by p38 MAPK-dependent activation of Caspase 3 and myeloid differentiation in a NFκB-dependent manner. By using murine AML cells, we demonstrate that p53 is dispensable for Pam3CSK4-induced apoptosis and differentiation. Moreover, murine -driven AML cells also were forced into apoptosis and differentiation on TLR1/TLR2 activation, demonstrating that the antileukemic effects observed were not confined to -rearranged AML. We further evaluated whether Pam3CSK4 would exhibit selective antileukemic effects. Ex vivo Pam3CSK4 treatment inhibited murine and human leukemia-initiating cells, whereas murine normal hematopoietic stem and progenitor cells (HSPCs) were relatively less affected. Consistent with these findings, primary human AML cells across several genetic subtypes of AML were more vulnerable for TLR1/TLR2 activation relative to normal human HSPCs. In the AML mouse model, treatment with Pam3CSK4 provided proof of concept for in vivo therapeutic efficacy. Our results demonstrate that TLR1 and TLR2 are upregulated on primitive AML cells and that agonistic targeting of TLR1/TLR2 forces AML cells into apoptosis by p38 MAPK-dependent activation of Caspase 3, and differentiation by activating NFκB, thus revealing a new putative strategy for therapeutically targeting AML cells.

Citing Articles

Toll-like receptor 1/2 activation reduces immunoglobulin free light chain production by multiple myeloma cells in the context of bone marrow stromal cells and fibronectin.

Abdi J, Redegeld F PLoS One. 2025; 20(1):e0310395.

PMID: 39874349 PMC: 11774389. DOI: 10.1371/journal.pone.0310395.


Immune checkpoints and ncRNAs: pioneering immunotherapy approaches for hematological malignancies.

Anvari S, Nikbakht M, Vaezi M, Amini-Kafiabad S, Ahmadvand M Cancer Cell Int. 2024; 24(1):410.

PMID: 39702293 PMC: 11660508. DOI: 10.1186/s12935-024-03596-8.


Bacterial surface lipoproteins mediate epithelial microinvasion by .

Chan J, Ramos-Sevillano E, Betts M, Wilson H, Weight C, Houhou-Ousalah A Infect Immun. 2024; 92(5):e0044723.

PMID: 38629841 PMC: 11075461. DOI: 10.1128/iai.00447-23.


Significance of TLR2 signaling during megakaryocyte development: regulatory cross-talk of miR-125b, cytokine induction, and MAPK pathway during dengue infection.

Malleswarapu M, Kovuru N, Khan N, Mishra A, Gutti R Am J Transl Res. 2023; 15(10):5972-5983.

PMID: 37969204 PMC: 10641356.


Bacterial lipoprotein plays an important role in the macrophage autophagy and apoptosis induced by and .

Jiang S, He J, Zhang L, Zhao Q, Zhao S Open Life Sci. 2023; 18(1):20220739.

PMID: 37791056 PMC: 10543702. DOI: 10.1515/biol-2022-0739.


References
1.
Bottero V, Withoff S, Verma I . NF-kappaB and the regulation of hematopoiesis. Cell Death Differ. 2006; 13(5):785-97. DOI: 10.1038/sj.cdd.4401888. View

2.
Muller C, Trepel M, Kunzmann R, Lais A, Engelhardt R, Lubbert M . Hematologic and molecular spontaneous remission following sepsis in acute monoblastic leukemia with translocation (9;11): a case report and review of the literature. Eur J Haematol. 2004; 73(1):62-6. DOI: 10.1111/j.1600-0609.2004.00248.x. View

3.
Askmyr M, Agerstam H, Hansen N, Gordon S, Arvanitakis A, Rissler M . Selective killing of candidate AML stem cells by antibody targeting of IL1RAP. Blood. 2013; 121(18):3709-13. DOI: 10.1182/blood-2012-09-458935. View

4.
. Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 1988;72(2):567-572. Blood. 2016; 128(26):3017. DOI: 10.1182/blood-2016-11-750182. View

5.
Jaras M, Miller P, Chu L, Puram R, Fink E, Schneider R . Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia. J Exp Med. 2014; 211(4):605-12. PMC: 3978274. DOI: 10.1084/jem.20131033. View